Constellation Pharmaceuticals Stock Forecast, Price & News

+0.74 (+3.74 %)
(As of 05/11/2021 04:30 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume414,104 shs
Average Volume461,965 shs
Market Capitalization$982.24 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for Constellation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Constellation Pharmaceuticals logo

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CNST
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$8.23 per share


Net Income$-85,550,000.00




Market Cap$982.24 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.15 out of 5 stars

Medical Sector

980th out of 2,045 stocks

Pharmaceutical Preparations Industry

456th out of 771 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

Is Constellation Pharmaceuticals a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Constellation Pharmaceuticals stock.
View analyst ratings for Constellation Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Constellation Pharmaceuticals?

Wall Street analysts have given Constellation Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Constellation Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Constellation Pharmaceuticals

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) announced its earnings results on Sunday, May, 9th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.05.
View Constellation Pharmaceuticals' earnings history

How has Constellation Pharmaceuticals' stock been impacted by COVID-19?

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CNST stock has decreased by 37.1% and is now trading at $20.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CNST?

7 brokers have issued 1 year price targets for Constellation Pharmaceuticals' stock. Their forecasts range from $20.00 to $53.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $40.33 in the next twelve months. This suggests a possible upside of 96.7% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the following people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Chief Financial Officer (Age 60, Pay $562.98k)
  • Dr. Patrick Trojer Ph.D., Sr. VP & Chief Scientific Officer (Age 48, Pay $556.52k)
  • Ms. Karen Higgins Valentine J.D., Sr. VP, Chief Legal Officer & Gen. Counsel (Age 49, Pay $535.93k)
  • Dr. Jeffrey Humphrey M.D., Chief Medical Officer (Age 59, Pay $462.25k)
  • Dr. Danny Reinberg, Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder
  • Dr. David Allis, Co-Founder
  • Mr. Mohan Bala Ph.D., Chief Operating Officer
  • Mr. Ronald Aldridge, Sr. Director of Investor Relations (Age 67)

What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO?

10 employees have rated Constellation Pharmaceuticals CEO Jigar Raythatha on Jigar Raythatha has an approval rating of 100% among Constellation Pharmaceuticals' employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Who are Constellation Pharmaceuticals' major shareholders?

Constellation Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.53%), Lord Abbett & CO. LLC (4.09%), Victory Capital Management Inc. (3.32%), Jennison Associates LLC (2.38%), Regents of The University of California (1.30%) and Peregrine Capital Management LLC (0.58%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals

Which institutional investors are selling Constellation Pharmaceuticals stock?

CNST stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California, Alliancebernstein L.P., Jennison Associates LLC, Los Angeles Capital Management LLC, Russell Investments Group Ltd., Principal Financial Group Inc., Virginia Retirement Systems ET AL, and Rhumbline Advisers. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, and Mark A Goldsmith.
View insider buying and selling activity for Constellation Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Constellation Pharmaceuticals stock?

CNST stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Peregrine Capital Management LLC, Lord Abbett & CO. LLC, Rafferty Asset Management LLC, BlackRock Inc., Altium Capital Management LP, BNP Paribas Arbitrage SA, and Swiss National Bank. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $20.50.

How much money does Constellation Pharmaceuticals make?

Constellation Pharmaceuticals has a market capitalization of $982.24 million. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Constellation Pharmaceuticals have?

Constellation Pharmaceuticals employs 154 workers across the globe.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is

Where are Constellation Pharmaceuticals' headquarters?

Constellation Pharmaceuticals is headquartered at 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]

This page was last updated on 5/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.